Medical guideline

首页肿瘤学指南检索结果

检索结果

按发表年份

共搜索到3条与Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available有关的结果

An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接